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Introduction
Chronotherapy is a medically established symptom-based 
treatment strategy of unequally dosing commonly prescribed 
medications or therapies to enhance therapeutic action on “tar-
get tissues” in chronic disease.1 In epilepsy, antiepileptic drug 
(AED) chronotherapy, commonly known as differential dos-
ing, requires a larger AED dose at the time of day or night 
when circadian-modulated biorhythms linked to seizure exac-
erbation are predicted to peak.
Differential dosing is an emerging means to safely optimize 
AED efficacy for improved seizure control particularly in 
selected childhood epilepsies that follow circadian patterns of 
seizure exacerbation and remission.2,3 There is evidence that 
differential dosing can extend seizure control and delay or pre-
vent drug resistance—a major risk factor in both status epilep-
ticus (SE) and sudden, unexpected death in epilepsy 
(SUDEP).3,4 Despite the credible research demonstrating the 
utility of differential dosing, medical practitioners have been 
slow to accept it as the preferred intervention in pediatric sei-
zure management. Conventional or equally divided AED dos-
ing is commonly prescribed to treat all epilepsy types. 
Differential dosing is mainly used to treat acute seizure emer-
gencies often resulting from drug resistance secondary to failed 
conventional AED dosing.4
Drug Resistance in Epilepsy
Chronic epilepsy affects nearly 500 000 children in the United 
States, and 30% will become drug resistant—a serious epi-
lepsy-related complication and a significant public health 
burden—related to inadequate or failed seizure control from 2 
or more conventionally dosed AEDs.5–10 Drug resistance pre-
sents more than an epilepsy management challenge; it is among 
the leading risk factors for SE and SUDEP.11–14 The danger of 
drug resistance and other SUDEP risk factors is often inade-
quately addressed in the literature.11 Research has shown that 
practitioners avoid discussing SUDEP with patients with epi-
lepsy, families, or caregivers.15
The hallmark of drug-resistant epilepsy is seizure clustering 
defined as a period of repetitive seizures with short interseizure 
intervals that fail to naturally terminate after 5 minutes.16 
Seizure clustering can lead to SE, a life-threatening encepha-
lopathy that requires rescue drugs to break and intensive care 
hospitalization.17 In the United States, the annual incidence of 
SE related and unrelated to drug resistance is approximately 20 
to 30 cases per 100 000, and children are twice as likely as 
adults to experience at least 1 episode of SE by the time they 
reach adulthood.18,19
Severe drug resistance is a major risk factor for SUDEP. 
Aptly described, SUDEP is the sudden, unexpected death of 
persons with epilepsy that occurs with or without witnesses, 
with or without postmortem evidence of seizure, and without a 
physical, traumatic, or toxicologic cause.11,13 Devinsky reported 
that among epileptic adults with one or more SUDEP risk fac-
tors, the incidence of SUDEP per 1000 patient-years is 6.0 to 
9.3. The annual mortality rates of SUDEP in infants and chil-
dren are considered unreliable but are suspected to be at least 
comparable to adults.11 Actual SUDEP cases in infancy are 
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believed to be underrecognized and underreported especially 
because unexplained death in infancy is often attributed to 
sudden infant death syndrome.20
The potential danger of drug-resistant epilepsy should 
motivate medical practitioners to initiate differential dosing 
early in the epilepsy diagnosis in selected cases not only to 
improve and prolong seizure control but also to reduce the risk 
of harmful or fatal outcomes.
Harmful Outcomes in Epilepsy
Current epilepsy research has proven the safety and efficacy of dif-
ferential dosing for children with chronic, circadian-driven cyclic 
epilepsy syndromes.3,4 Another benefit of differential dosing is 
longer seizure control which can delay or prevent drug resistance 
and reduce the risk of SE and SUDEP. The application of differ-
ential dosing for SUDEP prevention was recommended by 
Devinsky11 who boldly proposed increasing the nighttime AED 
dose in adults and children with nocturnal tonic-clonic (TC) epi-
lepsy as TC epilepsy is a known risk factor for SUDEP at any age.
The reluctance among many medical practitioners to imple-
ment differential dosing to treat cyclic seizures21 or to mitigate 
harmful outcomes could be alleviated with a credible hypoth-
esis of how AED chronotherapy works in epilepsy. This could 
motivate the medical community to use differential dosing for 
purposes of extending seizure control and to delay or prevent 
drug resistance and avert harmful outcomes.
Chronotherapy Use in Chronic Disease
The study and practice of chronotherapy in treating chronic 
disease are not new. Pharmacologic chronotherapy has a proven 
track record most notably in asthma, diabetes, and cancer treat-
ment. Burioka and colleagues22 described how chronotherapy 
can control life-threatening nocturnal asthma attacks and 
improve drug tolerance in adults with moderate-to-severe 
asthma. The authors reported that patients who had a night-
time dose of the bronchodilating agent theophylline during 
their circadian-modulated patient-specific phase of peak expir-
atory flow rate (PEFR) helped them predict and treat the early 
morning phase of low-level lung function more accurately and 
improve respiratory symptoms.22 Although the circadian phase 
of lowered lung function is necessary for pulmonary homeosta-
sis, reduced lung function in asthma disease can lead to severe 
asthma attacks.23
Chronotherapy in type 2 diabetes involves the application 
of long-acting and short-acting insulin preparations combined 
to cover predictable fluctuations in diurnal, circadian, and 
meal-based blood glucose levels. This strategy was specifically 
designed to target and prevent the harmful symptoms related 
to exogenous and endogenous circadian-modulated glucose 
peaks in patients with type 2 diabetes.24
Evidence linking improved outcomes in patients with 
advanced peripheral organ cancers with late afternoon chemo-
therapy treatments helped cancer researchers discover the 
optimal time to deliver cytotoxins and maximize cancer cell 
damage.25 The drug cisplatin is known to kill cancer cells by 
forming bulky lesions on DNA.26 Gaddameedhi and col-
leagues discovered that the circadian-modulated DNA nucleo-
tide excision repair (NER) pathway removes bulky DNA 
lesions induced by UV light and is highly active in the morning 
and less active in the afternoon.27–29 Patients who received cis-
platin chronochemotherapy in the afternoon during the endog-
enous phase of low NER pathway activity benefited from 
optimum cancer cell destruction and improved outcomes. 
Another advantage of chronochemotherapy is that patients 
reported less of the debilitating side effects suffered by patients 
on variably timed chemotherapy regimens.26–29 Despite these 
benefits, chronochemotherapy has yet to be accepted as a sig-
nificant therapeutic parameter in chemotherapy protocols.30
Certain childhood epilepsies like other chronic illnesses are 
influenced by circadian rhythms. Children with chronic cyclic 
epilepsy can be safely managed with AED chronotherapy and 
benefit from reduced drug toxicity and improved alertness. 
Despite the proven advantages of differential dosing to date its 
use is limited.3,4,31,32 The main reason why medical practition-
ers are reluctant to use differential dosing to treat epilepsy21 or 
chronochemotherapy to treat cancer30 is likely because a cred-
ible hypothesis of the underlying chronotherapeutic mecha-
nism has yet to be formalized. Unfortunately, this fact has likely 
impeded the advancement of chronotherapy use in chronic 
disease across many fields of medicine.
Suprachiasmatic Nucleus and Central Clock: The 
Circadian Link to Epilepsy
The molecular mechanism(s) involved in circadian seizure fre-
quency variations in humans is not well understood, but some 
mechanistic insight is available from animal models. The 
research by Ralph and colleagues33 established the suprachias-
matic nucleus as the site of the central biologic clock or circa-
dian pacemaker in mammals. The authors determined that the 
central pacemaker, commonly known as the circadian system, is 
a robust, dynamic equilibrating scheme responsible for driving 
gene expression in central and peripheral circadian oscillators 
necessary for metabolic equilibrium and homeostatic stability 
throughout the body.33 Damiola and colleagues34 provided fur-
ther evidence to support the existence of endogenous central 
and peripheral circadian oscillators in mammals that modulate 
biorhythms of energy homeostasis in 24-hour cycles.
The circadian involvement in mammalian epilepsy was 
demonstrated by Quigg and colleagues35 in rodents with 
mechanically induced mesial temporal lobe epilepsy (MTLE). 
The authors observed seizures occurred every 24 hours during 
the light cycle or sleep phase in nocturnal animals.35 In later 
research, Quigg36 reported that human subjects with MTLE 
had increased seizures in the early evening as the circadian-
initiated sleep phase approached.
These discoveries suggest that seizures in MTLE are acti-
vated close to or during the habitual sleep state in nocturnal 
and diurnal species secondary to a pathologic epileptic process 
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that disrupts the normal circadian-driven sleep state no matter 
when sleep occurs.
Circadian Regulation of Non-REM Sleep and 
Influence in Epilepsy
The complex phenomenon of sleep is highly conserved across 
species and is orchestrated by 2 mutually exclusive but interac-
tive mechanisms—the circadian oscillatory system and the 
homeostatic regulator—that together consolidate the sleep 
process.37,38 The circadian system’s role in sleep ontogeny is to 
initiate early non-rapid eye movement (NREM) sleep stages 
N1 and N2 and rapid eye movement (REM) cycles. The initia-
tion of REM sleep and the start and conservation of deep sleep 
or N3, commonly referred to as slow wave sleep (SWS), are 
believed to be under homeostatic control.38
Pavlova and colleagues39 shed some light on the circadian 
system’s role in normal sleep ontogeny and adverse involve-
ment in sleep-potentiated epilepsy. This research assessed the 
continuous day/night electroencephalographic (EEG) data of 
5 adult subjects with well-controlled TC epilepsy and quanti-
fied the wake/sleep variations of interictal epileptiform dis-
charges (IEDs). Interictal epileptiform discharges are benign 
EEG seizure patterns that do not evolve into electroclinical 
seizure events. Final results showed a predominance of IEDs in 
sleep compared with waking by a ratio of 14:1 (P < .001) and 
almost exclusively during the circadian-driven NREM sleep 
stages N1 and N2.39 Significantly, IEDs were found to be sup-
pressed during waking and during established REM sleep 
cycles,39 which is the physiologic element of sleep believed to 
be maintained by homeostatic regulators.38
These findings provide evidence supporting the circadian 
regulation of IEDs in adults with active, well-controlled TC 
epilepsy because IEDs were more prevalent in N1 and N2 
sleep. The fact that IEDs were greatly reduced in the homeo-
static-regulated REM cycles and when present failed to organ-
ize into electroclinical seizures further supports the circadian 
system’s regulation of early sleep and the intimate, adverse rela-
tionship between early sleep cycles and seizure activation in 
TC epilepsy.37–40
Stanley and colleagues examined data of complex networks 
of genes expressed in rodent brainstem nuclei and basal ganglia 
to illustrate the complexity of circadian gene regulation in what 
they referred to as a “bidirectional relationship” between diur-
nal rhythms and cyclic epilepsy. The authors suggested that 
epileptic seizures disturb endogenous circadian cycles of gene 
regulation in the central nervous system (CNS).41 Mirzoev and 
colleagues31 described the cyclic nature of seizures in various 
focal epilepsy types that are passively activated by the circadian 
rhythm of a gene or genes expressed in specific brain regions in 
24-hour cycles.
Mirzoev et  al more accurately described the relationship 
between endogenous circadian cycles and focal epilepsy patterns 
and provided insight as to why differential dosing works. The 
chronotherapy strategy when applied to epilepsy can improve 
and prolong drug efficacy and pharmacokinetic action when a 
greater AED dose is timed with the circadian period of peak 
seizure occurrence. Conversely, conventional dosing in circadian 
epilepsy can adversely affect AED pharmacokinetic properties 
by impeding absorption, metabolism, and excretion and lead to 
poor seizure control, drug toxicity, and drug resistance.9
Homeostatic Regulation and Relative Seizure 
Freedom of Slow Wave Sleep
Homeostatic-regulated SWS is believed to be a dynamic, 
restorative physiologic period necessary for the maintenance of 
peak metabolic and endocrine functions necessary for life.42,43 
Slow wave sleep in humans is also theorized to be a critical 
neurophysiologic period essential for memory consolidation 
and higher intellectual functions, including complex learn-
ing.44,45 The SWS pattern seen on EEG could possibly emu-
late a phase of lowered neocortical activity required for brain 
homeostasis in the same way that PEFR predicts when the 
phase of lowered lung function, necessary for normal pulmo-
nary homeostasis, will occur.23
The theory that SWS is critical for memory and learn-
ing44,45 while at the same time crucial for maintaining innate 
functions and the equilibria of multiple organ systems42,43 sug-
gests that SWS is vital for CNS homeostasis. The SWS pattern 
seen on EEG could possibly emulate a phase of lowered neo-
cortical activity required for brain homeostasis in the same way 
that PEFR identifies when the phase of lowered lung function, 
necessary for normal pulmonary homeostasis, will occur.23 As 
in asthma, when the phase of homeostatic-lowered lung func-
tion can lead to asthma attacks, the complex processes of brain 
homeostasis could require reduced neurophysiologic activity 
and result in neocortical excitability that in person predisposed 
to epilepsy can cause adverse symptoms.2 The onset of SWS 
could signal the endogenous phase of CNS homeostasis that in 
epilepsy can destabilize the neocortex before sleep transitions 
to lighter, circadian-driven NREM stages. This could be the 
scenario for seizure activation in autosomal dominant noctur-
nal frontal lobe epilepsy (ADNFLE). Seizure clusters begin 
approximately 2 hours after habitual sleep onset, at the end of 
the first SWS cycle, and early in the transition to N2 sleep.31,46 
Seizure activation in N2 lends credence to the theory of neo-
cortical destabilization3 and excitability2 during the homeo-
static-regulated SWS stage that precedes the circadian 
transition to N2 sleep. The nocturnal seizure pattern of 
ADNFLE in children and adults is very similar when time is 
adjusted for differences in sleep onset or bedtime. Seizure clus-
ters peak between 01:00 and 03:00 in children and 05:00 and 
07:00 in adults, at the same point of sleep ontogeny after SWS 
transitions to N2.3,31,46 These findings substantiate not only 
the inertness of SWS to activate, organize, or maintain electro-
clinical epileptic seizures but also its capacity to predispose the 
brain to seizure activation during early NREM stages.
The adverse association between early NREM sleep and sei-
zures is a significant fact often understated in epilepsy research. 
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Loddenkemper and colleagues acknowledged an intimate rela-
tionship between early NREM sleep and seizure activation 
based on EEG findings. The authors considered this only an 
assumption because the EEG data analyzed in their research 
were not recorded using the standard polysomnographic moni-
toring equipment used to stage sleep.3 But according to the 
work of Rechtschaffen and Kales,47 sleep stages can be accu-
rately identified using EEG data alone.
Evidence of Seizure Activation in Circadian N2 Sleep
Mirzoev and colleagues reviewed the literature of multiple 
EEG studies that investigated focal epilepsy in adults. They 
concluded that focal seizure cycles are predictable in both wak-
ing and sleep but peak at different times depending on the 
epileptogenic zone that generates them.31 The authors specu-
lated that although the area of brain onset dictates seizure 
semiology, the circadian cycle(s) specific to that brain region 
governed timing31 and used the seizure peak timing differences 
between frontal lobe and temporal lobes as examples. They 
observed that in frontal lobe disease, seizures peaked during 
NREM sleep more than 50% of the time. In contrast, temporal 
lobe seizures tended to peak in waking during the late after-
noon, an observation Quigg et  al35 reported in humans with 
MTLE. Mirzoev et al noted that in ADNFLE, nocturnal sei-
zures clustered consistently in N2 and speculated that 24−hour 
circadian phases activated generalized seizures in the same way. 
The authors referred to N2 as “spindle sleep” due to the char-
acteristic sine waves on EEG, as the sleep stage most suscepti-
ble to seizure activation due to an anomalous yet to be identified 
interrelationship with epilepsy.31
Regarding reports of exogenous melatonin treatment and 
nocturnal seizure exacerbation in adult epilepsy, Mirzoev et al31 
supported a causal relationship. The authors were likely influ-
enced by reports of an aberrant association between increased 
endogenous melatonin levels and seizure activation.9,48 The 
work by Pavlova and colleagues39 vindicated endogenous mela-
tonin as the cause of increased seizures. Pavlova et al noted that 
endogenous melatonin normally increases in N2 sleep possibly 
to promote, maintain, and advance habitual sleep. This makes 
the rise in melatonin a robust biomarker and the one sleep 
physiologists depend on to detect N2 sleep onset.39,49 The nat-
ural rise of melatonin in N2 sleep and the epileptogenicity of 
N2 sleep are associated but are distinct neurophysiologic phe-
nomena. This might explain why many epilepsy researchers 
believe that high amounts of melatonin can cause seizures.
Utility of Differential Dosing in Focal and 
Generalized Cyclic Epilepsy
The focal seizures of ADNFLE follow a cyclic pattern of sei-
zure exacerbation in sleep and remission in waking. Cyclic sei-
zure patterns are also common in generalized epilepsy.
X-linked infantile spasm syndrome 1 (ISSX1) is a form of 
epileptic infantile spasm seizures that is not formally recog-
nized by the International League Against Epilepsy (ILAE) as 
a generalized or sleep-activated epilepsy.7 Because the electro-
clinical seizures that characterize ISSX1 are considered cyclic, 
follow a strict circadian pattern of exacerbation and remission, 
and are followed by habitual sleep this important seizure type 
will be considered a sleep-potentiated generalized epilepsy 
type going forward.
Both ADNFLE and ISSX1 exhibit distinctive, cyclic, or cir-
cadian-driven electroclinical seizures2,3 activated in the early 
stages of circadian NREM sleep. Figure 1 shows a seizure in 
ADNFLE. The sleep-potentiated focal seizures tend to cluster 
approximately 2 hours after sleep onset and occur almost exclu-
sively during N2 sleep.31,46 Figure 2 shows a seizure onset in 
ISSX1. The epileptic infantile spasms that characterize ISSX1 
began to cluster at the transition period between circadian-mod-
ulated N1 sleep, or drowsiness,38 and morning awakening and 
when waking from naps.7,50,51 Although epileptic infantile spasm 
seizures resolve spontaneously after infancy, they commonly 
evolve into other complex focal and generalized seizure types 
that persist throughout life50,51 and often present many risk fac-
tors linked to SE and SUDEP, including severe drug resistance.
The differential dosing of a larger AED amount at bedtime 
in children with ADNFLE assures that the therapeutic drug 
level and mode of action reach peak performance during the 
circadian phase linked with predicated seizure risk.2,4 The 
lower AED dose commonly results in the natural fall of serum 
concentrations to nontherapeutic levels when seizure risk is 
low and leads to improved cognition, drug tolerance, and fewer 
side effects.4 The nontherapeutic AED levels during seizure 
remission might even provide the neocortex a respite from 
pharmacologic intervention which could improve overall brain 
function and prepare the brain to receive treatment more effi-
ciently when seizure risk is high.3,4
Epilepsy Research on the Application of AED 
Chronotherapy in Children
AED chronotherapy research in adult and pediatric popula-
tions has provided evidence in support of differential dosing as 
Figure 1. Electroencephalographic seizure sample of a preteen with 
autosomal dominant nocturnal frontal lobe epilepsy. The first of 3 
seizures in a cluster began after midnight. The focal seizures originated 
in the right frontal lobe (Fp2 lead). At seizure onset, the child lay 
motionless with eyes open for 3 to 4 seconds and then began thrashing 
the limbs vigorously, fist punching, nonsensical verbalization, and 
screaming. Referenced from Tomonoh et al.52
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a safe and effective method of controlling epilepsy, maintaining 
therapeutic drug concentrations, and reducing drug toxicity 
and side effects.3,4,31,32
For children with chronic epilepsy syndromes, Guilhoto and 
colleagues4 proved that differential dosing was particularly effi-
cacious in reducing or suppressing focal and generalized epi-
lepsy types that exhibited predictably timed seizure clusters 
presumed to be associated with endogenous circadian rhythms. 
Guilhoto et  al analyzed the medical records of 17 children 
between 3.5 and 21 years of age with various chronic seizure 
types, including ADNFLE, hospitalized for acute seizure clus-
tering, and treated with differential AED dosing. The authors 
assessed the safety and efficacy of differential dosing in com-
parison with the conventional dosing schedules all of the chil-
dren were formerly prescribed. Seizure diagnoses were based 
on the findings of long-term audiovisual EEG data collected 
over several consecutive days and according to ILAE seizure 
classification.7 Individual cases were followed and reevaluated 
after a 12-month period.4
Guilhoto et  al provided strong evidence to support the 
safety and efficacy of differential dosing particularly in the 
treatment of cyclic seizures in children. In cases of TC epi-
lepsy, the larger nighttime AED dose resulted in improved 
seizure control. Figure 3 illustrates how the larger nighttime 
dose of carbamazepine leads to peak therapeutic levels at the 
time of peak seizure risk. This finding could indicate the 
brain’s greater susceptibility to targeted treatment at night54 
and/or more efficient pharmacokinetic action of carbamaz-
epine during habitual sleep.9 The lower daytime AED dose 
resulted in lowered therapeutic drug levels during the school 
day and benefited children with improved energy and 
alertness.3
Guilhoto et  al proved that differential dosing resulted in 
faster, improved outcomes in children with focal and general-
ized nocturnal epilepsies compared with the control group of 
children treated with conventional dosing. Children tolerated 
differential dosing better than conventional dosing and showed 
less toxicity and fewer side effects. The final results were 
impressive and revealed that differential dosing lead to seizure 
freedom in 64.7% of children and seizures reduced by half in 
88.2% of children.4
Guilhoto et al supported the circadian involvement in sei-
zure activation. They reported that a close relationship exists 
between day/night circadian patterns and seizures in epilepsy 
and suggested that the normal alternations of excitatory and 
inhibitory thalamocortical circuits involved in the circadian 
regulation of NREM sleep could behave pathologically and 
stimulate seizures in the epileptic brain.4
Loddenkemper and colleagues3 presented a comprehen-
sive case study analysis of 1008 seizures in 225 children diag-
nosed with various focal and generalized epilepsy types. The 
authors found that the state of consciousness, waking or 
sleep, was a more accurate marker of seizure type and origin 
of onset than the time of day when seizures occurred. This 
reinforced the circadian system’s control of sleep and the 
influence of circadian phases on seizure exacerbation in and 
out of sleep.
Regarding epilepsy diagnosis and treatment, Loddenkemper 
and colleagues2 expounded on the dynamic interaction 
between sleep and epilepsy and the genetic regulation of epi-
lepsy by the circadian system during sleep. The authors pro-
vided a clearer understanding of the circadian process and 
role in seizure activation and the success of AED chrono-
therapy in controlling circadian-dependent seizures. The 
authors supported the utility of differential dosing in selected 
circadian-regulated epilepsy syndromes and suggested that 
the improved efficacy of AED chronotherapy is a way to pro-
vide patient-oriented treatment in cases of circadian-depend-
ent seizures.2 Loddenkemper et  al legitimated the term 
chronoepileptology in reference to differential dosing and the 
use of “zeitgebers” such as light therapy to help realign shifted 
circadian phases suspected in specific cases of increased sei-
zure activation.2,41
Figure 2. Electroencephalographic (EEG) seizure sample of an infant 
with X-linked infantile spasm syndrome 1. Epileptic spasm seizures 
began on awakening and continued over several minutes. Abnormal EEG 
activity preceded repetitive episodes of high amplitude, polymorphic 
spike, and slow wave complexes or “bursts” clinically associated with 
body flexion. Low amplitude or “suppressed” faster rhythms were 
associated with tonic stiffening of the limbs. Referenced from 
Panayiotopoulos53 (Chapter 7, Figure 7.1).
Figure 3. Equal and differential antiepileptic drug (AED) dosing in 
nocturnal epilepsy. Equal (ED) and differential (DD) dosing of the AED 
carbamazepine used to treat nocturnal tonic-clonic epilepsy. The daytime 
peaks of serum drug levels associated with DD are lower than in ED. 
Nighttime levels are higher with DD when seizures are known to peak. 
Referenced from Guilhoto et al.4
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Zarowski and colleagues32 provided evidence gathered from 
the retrospective analysis of a large cohort of children hospital-
ized for the management of chronic, predictable, sleep-related 
generalized epilepsy. In this study, seizure diagnoses were 
deemed highly reliable and based on ILAE classification 
standards7 and results from consecutive days of audiovisual 
EEG monitoring, seizure tracking logs prepared by parents 
and caregivers, and close adherence to AED dosing schedules. 
The authors reported that sleep-potentiated generalized sei-
zures were activated either from established sleep or when aris-
ing from sleep. They stressed the importance of distinguishing 
between evening and morning seizure preponderance and sug-
gested that the circadian system regulates certain generalized 
epilepsies.32 Zarowski et al32 also reported seizure predictability 
based on the fact that generalized cyclic seizures in children 
were more common in sleep and that epileptic infantile spasm 
clusters showed 2 peaks both associated with the transition of 
sleep to waking in the morning and from the afternoon nap.
Although the expert research analyzed in this review substan-
tiates the safety and efficacy of differential dosing in controlling 
certain childhood epilepsy syndromes, the more common appli-
cation of differential dosing is in response to acute seizure clus-
tering secondary to drug resistance—often the outcome of 
inadequate AED choice or dosage.3,4,9,32,55 The most common 
approach to managing drug-resistant epilepsy and the one rec-
ommended by the ILAE is AED substitution—a strategy that 
in itself presents new risks.7,8,56 AED manipulations in the set-
ting of increased seizures augment the likelihood of drug toxicity 
and other adverse side effects.4 Multiple AED use or polyther-
apy is another serious risk factor linked to SUDEP.11,14
The fact remains that as new AEDs are trialed often over 
several months and medication adjustments are made to offset 
new side effects, children continue to suffer with debilitating 
seizures that lead to marked cognitive impairment, overall 
delayed development, and steady reduction in the quality of 
life. Cho reported that epilepsy specialists are often unwilling 
to prescribe differential AED dosing in new cases of epilepsy 
mainly because there is no viable hypothesis of the chrono-
therapeutic mechanism.21 The use of differential dosing in the 
acute management of seizure clustering further perpetuates the 
notion that differential dosing is an emergency treatment and 
not a method to extend seizure control. The main reason for 
the limited use of the differential AED dosing method is likely 
because differential dosing contradicts ILAE’s expectation of 
equally divided AED dosing as the standard of care.
Research Results of Differential Dosing in Adults 
Extrapolated to Children
Mirzoev and colleagues31 reported positive findings of differ-
ential AED dosing in adults, including improved seizure con-
trol, reduced AED toxicity, and maintenance of therapeutic 
drug levels. The authors also suggested a lowered seizure 
threshold in the epileptic brain predominantly during N2 sleep 
secondary to aberrant signals that travel along the same tha-
lamic pathways known to generate the sleep spindles that char-
acterize N2 sleep.31 This observation has been corroborated by 
others in epilepsy research.2,4,40,41 Mirzoev et al31 noted simi-
larities between adult and childhood focal epilepsy types, 
including the consistent timing of day/night seizure peaks and 
stereotypical seizure patterns. These features of focal epilepsy 
depend on the area of seizure onset in the brain.
Yegnanarayan et  al54 performed one of the earliest and 
largest clinical trials of differential AED dosing efficacy. A 
cohort of 148 adult subjects diagnosed with and under treat-
ment for generalized, sleep-potentiated epilepsy were fol-
lowed for 12 months. Subjects were categorized according to 
their daily AED dosing amounts. The study subjects were 
differentially dosed and received 25% of the total daily AED 
dose in the morning and 75% in the evening or the entire 
dose in the evening. The control subjects were conventionally 
dosed and received equally divided doses twice daily. Both 
groups were closely monitored for AED compliance by caring 
family members.54
At the end of 1 year, the authors reported that the study 
group experienced faster seizure control and an improved over-
all response, including lowered seizure frequency and reduced 
adverse effects, and had achieved adequate drug maintenance 
levels. None of the control subjects experienced any positive 
results.54
According to an earlier adult study led by Yegnanarayan,54 
the evening dose of the AED phenytoin when compared with 
the morning dose showed a better pharmacokinetic effect, 
including faster and more efficient absorption and reduced 
toxicity and side effects. The improved response could have 
been due to better drug pharmacokinetic action in the evening 
hours related to habitual sleep.4 Similarly, in asthma, the 
nighttime prophylactic dose of theophylline improved lung 
function by morning in time for the endogenous circadian 
phase of reduced pulmonary function when the risk of asthma 
attacks was known to peak.22,23
Although most of the clinical trials and retrospective case 
studies of AED chronotherapy have been carried out in adult 
subjects,31,54 the benefits of differential dosing, including 
improved seizure control, reduced incidences of drug toxicity, 
and maintenance of therapeutic levels, can be extrapolated to 
children affected by the same epilepsy disorders.31 Other com-
mon features between adult and childhood epilepsy include 
the circadian influence of seizure exacerbation, the propensity 
for drug resistance, the risk of SE, and the fatal outcome of 
SUDEP.
Methods
•• Four retrospective case study investigations of AED 
chronotherapy use in up to 225 children ranging from 
3 months to 20 years with various pediatric seizure 
types and AED treatment schedules were evaluated. 
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Children were hospitalized for acute seizure clustering 
secondary to drug resistance while on conventional 
AED dosing.
•• Seizure diagnoses were made according to ILAE seizure 
classification, and AEDs were prescribed according to 
ILAE treatment guidelines.
•• The chronotherapy method was assessed in subjects 
who received a greater amount of the total daily AED 
dose based on the predictable circadian patterns of day/
night seizure peaks. The lower amount was given during 
the predicted period of seizure remission.
•• With the exception of the review by Mirzoev et al,31 sei-
zure diagnoses were based on results from at least 1 day 
and up to 10 consecutive days of audiovisual EEG mon-
itoring during extended hospitalizations in tertiary epi-
lepsy centers. Parents or caregivers prepared detailed 
written seizure logs to track seizure frequency and report 
new seizure types. All patient-seizure information, 
AED, and dosing schedule were documented in elec-
tronic medical records during hospitalization.
•• Six general requirements were applied to each case study 
to test the claim that AED chronotherapy when com-
pared with conventional AED dosing can provide faster 
seizure control with fewer side effects in cases of acute 
seizure clustering.
Table 1 lists the 4 retrospective case studies analyzed in this 
review. All case studies observed and documented seizure 
exacerbation and remission patterns in subjects with chronic 
epilepsy. Each case study assessed the utility and safety and 
efficacy of differential AED dosing. Three of the case studies 
evaluated the potential use of differential AED dosing to 
treat focal and/or generalized epileptic seizures,3,31,32 and 1 
study was treatment based4 and examined actual differential 
AED dosing results in children with either focal or general-
ized epilepsy.
Tables 2 to 5 highlight the 6 general requirements applied 
to each case study, including the type of epilepsy under inves-
tigation, reliability of epilepsy diagnosis, observation of sei-
zure pattern, use of differential AED dosing, evidence of 
improved seizure outcome, and whether drug resistance was 
identified by the authors as a risk factor with potential harm-
ful consequences.
Results
Tables 6 to 9 include condensed synopses of each case study’s 
objective, methods, results, and final conclusions along with the 
authors’ retrospective interpretation of the original data. 
Individual case study findings of focal and generalized epilepsy 
are listed.
Loddenkemper et  al3 reported that the waking or sleep 
states are more reliable than daytime or nighttime hours at 
predicting seizure activation and confirming seizure types 
(Table 6).
Table 1. Case studies investigating antiepileptic drug chronotherapy.
Circadian patterns of pediatric seizures, Loddenkemper et al.3
Circadian profiles of focal epileptic seizures: A need for reap-
praisal, Mirzoev et al.31
Circadian distribution and sleep/wake patterns of generalized 
seizures in children, Zarowski et al.32
Higher evening antiepileptic drug dose for nocturnal and early 
morning seizures, Guilhoto et al.4
Table 2. Requirements to test the hypothesis applied to circadian 
patterns of pediatric seizures.
REqUiREMENT REqUiREMENT MET
Seizure type(s) identified Yes (focal and generalized)
Reliable epilepsy diagnoses Yes (based on iLAE seizure 
classification, LTM, electronic 
medical records, and seizure 
tracking logs)
Differential AED dosing 
schedules used
N/A
Patterns of seizure exacerba-
tion and remission observed
Yes
Evidence of improved seizure 
outcomes and reduced side 
effects secondary to differen-
tial AED treatment
N/A
Associated drug resistance 
with harmful consequences
No
Abbreviations: AED, antiepileptic drug; iLAE, international League Against Epi-
lepsy; LTM, long-term monitoring.
Table 3. Requirements to test the hypothesis applied to circadian 
profiles of focal epileptic seizures: a need for reappraisal.
REqUiREMENT REqUiREMENT MET
Seizure type(s) identified Yes (focal)
Reliable epilepsy diagnoses Sometimes (some focal 
seizure types were classified 
according to iLAE classifica-
tion and nonvideo EEG 
findings)
Differential AED dosing 
schedules used
N/A, although discussed
Patterns of seizure exacerbation 
and remission observed
Yes
Evidence of improved seizure 
outcomes and reduced side 
effects secondary to differential 
AED treatment
N/A
Associated drug resistance with 
harmful consequences
No
Abbreviations: AED, antiepileptic drug; EEG: electroencephalographic; iLAE, 
international League Against Epilepsy.
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In focal epilepsy, the brain’s origin of seizure onset can influ-
ence local circadian rhythms which can lead to seizure peaks.
Mirzoev et al31 reported that AED treatment in focal epi-
lepsy has been negatively affected by the fact that the circadian 
influence in focal epilepsy is underappreciated. Predictable 
seizure patterns and mechanisms of activation in adult focal 
epilepsy types are similar in childhood forms. A credible 
hypothesis of the aberrant mechanism(s) that connects normal 
circadian rhythms with epileptic events is sorely needed and 
will require a collaboration of several sciences to accomplish 
(Table 7).
Zarowski et al32 reported that the predictable timing differ-
ences in seizure clustering among various focal and generalized 
childhood epilepsies are secondary to separate, distinct circa-
dian rhythms that regulate seizure activation to predominate in 
either the waking or sleep state (Table 8).
The treatment-based research by Guilhoto et al4 found that 
children with predictable focal nighttime and generalized day-
time 24-hour seizure cycles who developed drug resistance and 
acute seizure clustering while on conventional dosing sched-
ules regained seizure control quickly and with few side effects 
secondary to the differential dosing of 75% of the total AED 
amount at night (Table 9).
Common findings among all 4 case studies are listed:
•• All case studies supported the circadian oscillatory sys-
tem’s involvement in seizure propagation in cyclic epi-
lepsy based on the predictability of seizure exacerbation 
and remission and promoted this observation as the 
most significant factor to support the need for AED 
chronotherapy.
•• Seizure clusters that occurred during habitual nighttime 
sleep were considered sleep potentiated. Seizure clusters 
that occurred on morning awakening were considered 
daytime events.
•• All case studies supported the classification of epileptic 
infantile spasm seizures as nongeneralized waking 
events.
•• All case studies missed the opportunity to emphasize 
the need for AED chronotherapy by acknowledging the 
success of differential AED dosing not only as a safe and 
effective method of controlling acute seizure clustering 
but also as a means to improve and extend seizure con-
trol and expressly to avert or prevent drug resistance, a 
known epilepsy-related consequence that affects 30% of 
children with epilepsy and is a major risk factor in both 
SE and SUDEP.
Discussion
Each retrospective case study analyzed in this review agrees 
that differential AED dosing is safe and effective in cyclic sei-
zure management. None addressed the need for differential 
AED dosing to prolong seizure control or prevent drug resist-
ance. This was very concerning because drug resistance is a 
known epilepsy-related consequence that affects 30% of chil-
dren treated with conventional AED dosing and a major risk 
factor in SE and SUDEP.13,56
The reluctance among researchers to acknowledge the need 
for AED chronotherapy to treat selected epilepsy types or to 
delay or prevent drug resistance is most likely because the 
ILAE holds an impartial position on differential AED dosing. 
Table 4. Requirements to test the hypothesis applied to circadian 
distribution and sleep/wake patterns of generalized seizures in 
children.
REqUiREMENT REqUiREMENT MET
Seizure type(s) identified Yes (generalized)
Reliable epilepsy diagnoses Yes (based on iLAE seizure 
classification, LTM, electronic 
medical records, and seizure 
tracking logs)
Differential AED dosing 
schedules used
N/A
Observed patterns of seizure 
exacerbation and remission
Yes
Evidence of improved seizure 
outcomes and reduced side 
effects secondary to differential 
AED treatment
N/A
Associated drug resistance with 
harmful consequences
No
Abbreviations: AED, antiepileptic drug; iLAE, international League Against Epi-
lepsy; LTM, long-term monitoring.
Table 5. Requirements to test the hypothesis applied to higher 
evening antiepileptic drug dose for nocturnal and early morning 
seizures.
REqUiREMENT REqUiREMENT MET
Seizure type(s) identified Yes (focal and generalized)
Reliable epilepsy diagnoses Yes (based on iLAE seizure 
classification, LTM, electronic 
medical records, and seizure 
tracking logs)
Differential AED dosing 
schedules used
Yes (differential AED dosing was 
compared with conventional AED 
dosing schedules in treating 
focal and generalized epilepsy 
types)
Observed patterns of seizure 
exacerbation and remission
Yes
Evidence of improved 
seizure outcomes and 
reduced side effects 
secondary to differential 
AED treatment
Yes (positive correlation made 
between differential AED dosing 
and focal and generalized 
seizure control with seizures that 
follow predictable patterns of 
exacerbation and remission)
Associated drug resistance 
with harmful consequences
No
Abbreviations: AED, antiepileptic drug; iLAE, international League Against Epi-
lepsy; LTM, long-term monitoring.
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The ILAE neither supports nor opposes the application of 
differential AED dosing under any circumstance. But the 
ILAE appears to presume that AEDs are prescribed according 
to conventional dosing standards.7 In this regard, nonconven-
tional AED dosing challenges the standard of care expected 
by ILAE although this is only an assumption.
Table 6. Case study objective and synopses of methods, results, and conclusions.
METHODS RESULTS CONCLUSiONS
Two-year retrospective case study review of 
1008 primary seizures in 225 children aged 
2.5 to 14 years hospitalized for the acute 
increase in focal or generalized seizures 
determined to be resistant to conventional 
AED dosing
Waking and sleep are more reliable for 
predicting seizures, accurate seizure classifi-
cation, and AED management particularly 
for epilepsy syndromes influenced by 
circadian rhythms. Nocturnal focal seizures 
occurred more often in sleep (00:00-06:00), 
and generalized seizures occurred more 
often on awakening (06:00-12:00)
The “epileptogenic zone” or brain origin of 
seizure onset likely influences cyclic seizure 
peaks of circadian rhythm(s) that predomi-
nate during a period of cortical susceptibility 
to seizure activation. Waking or sleep can 
predict seizure origin of onset, semiology, 
and the incidence of clustering secondary to 
circadian influences over sleep and epilepsy
Abbreviations: AED, antiepileptic drug.
Loddenkemper et al assessed whether waking and sleep were more reliable markers than day and night in predicting focal and generalized pediatric seizure patterns.
Table 7. Case study objective and synopses of methods, results, and conclusions.
METHODS RESULTS CONCLUSiONS
Retrospective analyses of the current 
epilepsy research that reported on the peak 
timing differences among various focal 
seizures in adults (and children) as a 
function of the brain’s origin of cortical onset
Circadian periodicity of focal epileptic 
seizures exists in adults, and differences in 
seizure timing are based on the origin of 
cortical seizure onset. Adult focal seizure 
patterns are very similar in children. Seizure 
clustering in adult cases of ADNFLE peak 
between 05:00 and 07:00 and between 01:00 
and 03:00 in children (due to an earlier 
bedtime)
The circadian influence of focal epilepsies is 
underappreciated. This fact impacts AED 
treatment. The collaboration of epileptology 
and chronobiology could lead to the 
discovery of the aberrant mechanism(s) 
involved in circadian seizure exacerbation 
and novel treatments and improve focal and 
generalized epilepsy management
Abbreviations: ADNFLE, autosomal dominant nocturnal frontal lobe epilepsy; AED, antiepileptic drug.
Mirzoev et al reviewed multiple case studies to determine whether circadian phases (acting on the brain’s origin of seizure onset) are responsible for the timing differ-
ences known to occur among various types of focal epileptic seizures.
Table 8. Case study objective and synopses of methods, results, and conclusions.
METHODS RESULTS CONCLUSiONS
Five-year retrospective study of 316 seizures 
in 77 children aged 3 months to 20 years 
hospitalized for drug-resistant focal or 
generalized (TC) epilepsy. Seizure clusters 
occurring between 06:00 and 18:00 were 
classified as daytime. Seizure clusters that 
occurred between 18:00 and 06:00 were 
classified as nocturnal
Different types of generalized seizures cluster at 
different times more than 24 hours because they 
are driven by separate, endogenous circadian 
rhythms. Most TC seizures cluster at night 
between 18:00 and 06:00. infantile spasms 
(central to iSSX1) cluster in waking in the early 
morning 06:00-09:00 and again around 15:00 
but could be associated with drowsiness (N1)
Pediatric-generalized epileptic seizure 
exhibits an awake or sleep predomi-
nance according to type. This distinction 
and accurate seizure diagnosis can help 
guide individualized treatment, including 
differential AED dosing schedules and 
other treatment options
Abbreviations: AED, antiepileptic drug; iSSX1, X-linked infantile spasm syndrome 1; TC, tonic-clonic.
Zarowski et al assessed the timing of seizure clusters associated with various types of TC epilepsy relative to distinct circadian phases active in the sleep or waking 
states.
Table 9. Case study objective and synopses of methods, results, and conclusions.
METHODS RESULTS CONCLUSiONS
One-year retrospective case study of 17 
children aged 3.5 to 20 years hospitalized for 
drug-resistant nocturnal focal or generalized 
(TC) early morning epileptic seizures treated 
with differential AED dosing with ¾ of the 
total daily dose taken at night
Differential AED dosing resulted in seizure 
freedom in 64.7% of cases and in reduced 
seizure frequency in 88.2%
Differential AED dosing ¾ of the total daily 
dose at night proved to be safe and more 
effective than conventional equally divided 
AED dosing by providing better seizure 
control in drug-resistant pediatric epilepsies 
associated with predicable circadian seizure 
patterns
Abbreviations: AED, antiepileptic drug; TC, tonic-clonic.
Guilhoto et al assessed the efficacy of differential AED dosing in the acute seizure management of children with focal and generalized drug-resistant epilepsy on conven-
tional AED dosing.
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Limitations of the Case Studies
The research by Guilhoto and colleagues examined the efficacy 
of differential dosing to regain seizure control in focal epilepsy, 
including ADNFLE and generalized nocturnal TC seizures. 
Although results of differential dosing in cases of epileptic 
infantile spasms were reported, subjects diagnosed with infan-
tile spasms or subjects who had an early diagnosis of epileptic 
infantile spasms that had naturally evolved into other seizure 
types after infancy were not included. The omission of this 
important generalized seizure type with all the earmarks of 
circadian-driven epilepsy and the one very well suited for dif-
ferential dosing left the treatment of epileptic infantile spasms 
unchallenged. One possible reason is that epileptic infantile 
seizure spasms are not classified as focal or generalized seizures 
nor are they considered sleep potentiated by most of the inves-
tigators (or by the ILAE) even though the seizure clusters that 
characterize epileptic infantile spasms are generalized and 
closely follow habitual sleep and are activated as sleep transi-
tions to the waking state in the morning and after naps.50,51
Guilhoto et  al speculated on the possible relationship 
between CNS seizure mechanisms and patterns of circadian-
modulated seizures and considered pharmacokinetic differ-
ences among AEDs specifically regarding absorption and 
elimination rates and peak levels but did not ponder how the 
chronotherapeutic mechanism enhanced AED action with 
respect to the circadian timing of seizures.4 In support of the 
circadian involvement in seizure activation, the authors 
reported that a close relationship exists between day/night cir-
cadian patterns and seizures in epilepsy. They also suggested 
that the normal alternations of excitatory and inhibitory 
thalamocortical circuits involved in the circadian regulation of 
NREM sleep could behave pathologically and stimulate cer-
tain seizure types in the epileptic brain.4 Although the authors 
supported the circadian regulation of NREM sleep and patho-
logic influence of epilepsy in circadian NREM sleep, they did 
not comment whether or not N2 sleep was more susceptible to 
seizure activation.
Although their results were promising, Guilhoto et  al 
remained skeptical and concluded that differential AED dos-
ing alone could not explain such impressive results.4 This was 
mainly due to the fact that the greater AED dose at night led 
to improved seizure control with only minor drug level peaks.4 
This finding could have prompted them to consider that mini-
mal AED peaks reflected improved pharmacokinetic activity 
provided by the higher nighttime dose. Ramgopal and col-
leagues9 indirectly suggested this possibility when reporting 
that the endogenous central and peripheral circadian oscillators 
necessary for regulating brain functions and metabolic activity 
in distant organ systems could positively or negatively affect 
AED pharmacokinetic efficacy.
Loddenkemper and colleagues reported that the complex 
circadian-driven sleep processes that produce robust sleep spin-
dles—the characteristic feature of N2 sleep—follow the same 
inhibitory and excitatory thalamocortical oscillatory pathways 
theorized to generate seizures in epilepsy.3,40,46 The work by 
Loddenkemper et al3 was poised to expand on the strict circa-
dian influence of epilepsy in early sleep with data highlighting 
seizure activation in N1 and N2, but did not speculate further 
because the EEG data analyzed in their research were not 
recorded according to the polysomnographic monitoring stand-
ards currently used for proper sleep staging. The authors were 
correct in identifying N2 as the circadian sleep stage of seizure 
activation in ADNFLE in children and adults3 and could have 
implicated early sleep in seizure activation based on EEG data 
alone by applying the sleep stage scoring guidelines perfected by 
Rechtschaffen and Kales.47 Loddenkemper et al3 also reported 
that epileptic infantile spasms tend to occur more commonly in 
the waking state, but a close examination of the authors findings 
indicated that infantile spasms are more likely sleep stage 
dependent because seizure clusters are known to begin at the 
transition from early NREM sleep in the N1 or drowsy period 
that precedes morning awakening and awakening from 
naps.32,50,51 In this way, epileptic infantile spasms are more of a 
sleep-potentiated type of epilepsy.
Zarowski and colleagues determined that many generalized 
seizures occur during sleep, and the epileptic seizure clusters in 
infantile spasm occur during the transitional period from N1 
sleep to waking in 2 peaks—on morning awakening and wak-
ing from naps.3,32 The close association with N1 sleep and sei-
zure clustering in infantile spasms as suggested is actually a 
sleep-potentiated generalized seizure type prone to circadian 
seizure activation. Along the same line, Zarowski et  al also 
implied that the decreased cortisol levels found in infants diag-
nosed with epileptic infantile spasms were abnormal and pos-
sibly diagnostic of the disorder. It is known that cortisol and 
melatonin are circadian-driven hormones that naturally occur 
out of phase with each other across the 24-hour day (Figure 4). 
In fact, cortisol reaches trough levels in the late evening as mel-
atonin levels peak. The inverse relationship between cortisol 
and melatonin speaks not only to the strong circadian drive to 
Figure 4. The circadian-driven hormones cortisol and melatonin occur 
out of phase. Cortisol peaks during the waking hours and melatonin 
peaks during habitual sleep (http://www.thepaleomom.com/2014/02/
regulating-circadian-rhythm.html).
Manganaro et al 11
promote sleep and regulate endocrine functions4,32,39,43 but also 
to the possibility that the sleep process is integral to the activa-
tion of generalized seizures including epileptic infantile spasms.
Regarding hormone regulation, Loddenkemper et al3 iden-
tified a connection between the abnormal modulation of hor-
mones and seizure activation and suspected that, in certain 
epilepsies, circadian modulators of endocrine activity, and the 
neurohormone melatonin, are abnormally offset during the 
daytime and nighttime hours and can influence the waking and 
sleep seizure patterns associated with various focal and general-
ized epilepsies. The authors also speculated on the future of 
epilepsy management, including therapeutic treatments 
designed to reset circadian endocrine cycles in the waking and 
sleep states as a way to inhibit focal seizure activation at specific 
brain locations.3 This observation could have been expanded to 
explain how differential AED doing can help this process 
along with improving seizure outcomes.
The most significant inadequacy common to all the case 
studies was the fact that none warned against the dangerous 
connection drug resistance has with SE and SUDEP.
Chronotherapy Use in Chronic Diseases Including 
Epilepsy
Chronotherapy involves timing medical treatment(s) to align 
with the endogenous circadian rhythms involved in normal 
metabolic processes that in chronic disease states can “trigger” 
adverse symptoms. In asthma, the chronotherapeutic night-
time application of the bronchodilating agent theophylline is 
timed to coincide with the natural circadian phase of lowered 
pulmonary function—a state of normal lung homeostasis—
that in asthma sufferers can lead to life-threatening asthma 
attacks.22,23 In type 2 diabetes, the application of chronothera-
peutic insulin preparations can help minimize the adverse 
effects of normal day/night fluctuations of glucose peaks.24 In 
cancer treatment, cisplatin chronochemotherapy administered 
during a normally low circadian phase of NER activity can 
destroy more cancer cells and result in improved outcomes and 
reduced side effects.27–29
Guilhoto et  al4 reported that AED chronotherapy can 
preempt focal and generalized seizures that follow predictable 
circadian cycles of exacerbation and remission. The EEG sei-
zure clusters associated with epileptic infantile spasms and 
ADNFLE have been observed to begin in circadian-driven 
N1 and N2 sleep stages, respectively.46,50,51 Mirzoev et  al31 
speculated on the existence of an aberrant connection between 
the neuropathology of epilepsy and the N2 (spindle) sleep 
stage. Zarowski et al32 reported on the involvement of inhibi-
tory and excitatory thalamic circuits in the normal generation 
and synchronization of sleep spindles in NREM sleep, specifi-
cally N2, as well as the activation of seizures along the same 
pathways in epilepsy. Researchers agree that sleep involves 
complex interactions among various physiologic (circadian) 
oscillatory systems and networks that communicate with 
thalamic structures known to generate sleep spindles in N2 
sleep.3,4 Curiously, none of the authors addressed why N2 
sleep is especially seizure prone. This observation could have 
strengthened the circadian influence of seizures in ADNFLE 
and support the use of AED chronotherapy in selected cases.
Regarding the circadian influence of nocturnal seizures, the 
research by Loddenkemper and colleagues3 reported that sleep 
potentiated seizures but did not qualify the stage(s) of sleep 
where seizures most commonly occurred as part of their inves-
tigation. Loddenkemper et al stated that the reason for this was 
that the standard sleep monitoring parameters used to distin-
guish NREM stages and REM were not applied to the EEGs 
in the database. However, sleep staging or sleep stage scoring 
can be determined using EEG brain wave activity alone accord-
ing to the EEG sleep scoring guidelines prepared by 
Rechtschaffen and Kales.47 The confirmation of N1 and N2 
sleep in seizure activation could have strengthened and sup-
ported the differential AED dosing argument by linking the 
circadian control of early sleep with the circadian influence in 
epilepsy.
With the exception of Zarowski et al, most authors agreed 
that the epileptic infantile seizure spasms characteristic of 
ISSX1 are activated in the waking state. In a brief reference to 
established sleep staging criteria, Zarowski et al32 alluded to the 
possibility that epileptic infantile spasm seizures could be more 
closely related to drowsiness (the circadian-driven sleep stage 
N1) than to the waking state. This observation was accurate if 
one considers the EEG criterion described by Rechtschaffen 
and Kales47 and corroborated by Dijk and colleagues37,38 years 
later that distinguished N1 as the earliest stage of NREM 
sleep. In the field of EEG, N1 is also referred to as drowsiness 
and is characterized by the loss of posterior waking brain 
rhythms (alpha waves) and the appearance of continuous, low-
amplitude slower rhythms (theta waves) and the absence of 
sleep spindles.37,38 The versatility of N1 distinguishes it as a 
transitional stage that can advance to N2, precede REM, and 
transition the sleep state into the waking state. In this regard, a 
closer examination of the morning seizure clusters of ISSX1 
from a sleep physiology perspective would likely have con-
vinced most authors that epileptic infantile spasm seizure clus-
ters are not waking seizures at all but are in fact under circadian 
influence because they are activated in the sleep transitional 
stage N1. The fact that seizure activation does not occur from 
the homeostatic sleep-regulated stages of SWS or established 
REM further supports the circadian involvement and activa-
tion of seizures and defends differential AED dosing as a logi-
cal treatment strategy in selected cases.
More research is needed to determine why normal endoge-
nous circadian rhythms behave abnormally in the setting of 
epilepsy and how differential AED dosing improves seizure 
outcomes safely, and with fewer side effects than conventional 
dosing, in cases of drug-resistant seizure clustering. The chron-
otherapeutic response in epilepsy is in line with the beneficial 
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results provided by the chronotherapeutic strategies in manag-
ing other cyclic, chronic illnesses, such as asthma and diabetes 
mellitus, and in cancer treatment based on the cyclic phases of 
cellular vulnerability. A credible hypothesis of the chronothera-
peutic mechanism(s) in relation to pharmacokinetic properties 
of AEDs could reveal the success of differential dosing and the 
success of AED chronotherapy in seizure control. Improved 
AED pharmacokinetic designs and seizure prediction and 
detection technologies57,58 could also improve the lives of chil-
dren living with epilepsy.
In most of the case studies, seizure diagnoses were based on 
the results gathered from consecutive days of prolonged EEG 
monitoring in tertiary medical centers and seizure events 
logged and documented in electronic medical records. Seizure 
classifications and AED choices were made according to ILAE 
guidelines.7
In all case studies, authors either failed to report SE histo-
ries in their subjects or control for subjects with SE histories 
which likely confounded statistical analyses and final results 
because children with the history of SE who are commonly 
affected by more severe epilepsy types might not have responded 
to differential AED dosing in the same way as children with-
out a history of SE.
The Standard of Care: What Is Acceptable Medicine?
The success of AED chronotherapy in childhood epilepsy is 
based on the circadian influence of seizures that follow 24-hour 
circadian patterns of exacerbation and remission. But the stand-
ard of care set by the ILAE’s latest classification of epilepsy syn-
dromes and seizure types does not acknowledge a causal 
relationship between circadian rhythms and epilepsy in focal or 
generalized type of seizures. The ILAE does not imply the use 
of differential AED doing in cases of drug resistance.7 Although 
the ILAE formed a special task force for the express reason of 
defining drug-resistant epilepsy to medical practitioners to 
improve seizure outcomes in patients and to benefit epilepsy 
research, the ILAE referred to drug resistance relative to seizure 
“clustering” as a “pharmacoresistant occurrence to be expected 
along the natural course of certain epilepsy syndromes”57
Regarding AED treatment regimes, it appears that the 
ILAE assumes the use of conventional, equally divided dosing 
as the standard of care and neither acknowledges nor refutes 
differential AED dosing practices.7,8 In recent ILAE publica-
tions regarding the topic of drug resistance in epilepsy, differ-
ential AED dosing is not discussed not even as an alternative 
to failed conventional dosing regimens in acute seizure cluster-
ing or as a means to avert harmful epilepsy-related conse-
quences in patients with one or more SUDEP risk factors.7,8,57 
In fact, the ILAE’s recommendation for the treatment for 
“pharmacoresistance” is switching to a new AED as a mono-
therapy or in combination with other AEDs (polytherapy) at 
clinically effective dosages with the expectation that conven-
tional dosing schedules will be applied. From that point, 
seizure freedom was reported to require at least 12 months. 
The ILAE’s recommendation of AED substitution in drug-
resistant epilepsy is not without risks.
The ILAE describes epilepsy as a dynamic but tenuous neu-
rophysiologic process prone to ebb and flow along a natural 
course which can include pharmacoresistance.7 Epilepsy in 
remission can temporarily relapse in the setting of common 
stressors such as febrile illness or worsen more permanently 
over time and become refractory to the AED(s) that once pro-
vided good control.7,8,57 It appears that the ILAE proceeds 
with caution regarding differential dosing particularly in new 
or evolving epilepsy. This is likely because drug toxicity and 
side effects in conventional dosing can be severe and warrant 
immediate AED discontinuation.8,9,57 For these reasons, it 
would be safer to prescribe conventional, equally divided AED 
dosing from the onset even to treat cyclic seizures to manage 
drug toxicity in the event of refractory epilepsy. These are legit-
imate concerns implied by the ILAE based on the recommen-
dation of AED substitution and the expectation that 
conventional dosing schedules will be prescribed.
The way to create confidence in the application of AED 
chronotherapy is with a credible hypothesis that describes the 
circadian mechanism(s) in seizure exacerbation. An improved 
understanding of how AED chronotherapy works could lead to 
its wider use in acute drug-resistant epilepsy as well as in the 
primary management of cyclic seizures. This would require the 
collaboration of scientists across a broad range of medical dis-
ciplines, including epileptology, chronobiology, and sleep phys-
iology, to discover the chronotherapeutic mechanism and how 
AED chronotherapy works. An improved understanding of 
AED chronotherapy could lead to the research and develop-
ment of novel treatments, including smart drugs designed with 
improved pharmacokinetics capable of interacting with and 
disrupting the epileptic process and reducing the seizure bur-
den in children.
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